LIPO (Lipella Pharmaceuticals) Other Current Assets: $0.22 Mil (As of Sep. 2025)


LIPO Lipella Pharmaceuticals Inc LIPO
35 GF Score
Price $0.13
GF Value $8.69
Valuation Possible Value Trap
! 1 Warning Sign
View Full Analysis

What is Lipella Pharmaceuticals Other Current Assets?

Lipella Pharmaceuticals LIPO 35 Other Current Assets is $0.22 Mil as of Sep. 2025. GuruFocus rates LIPO with a GF Score™ of 35/100 and a GF Value™ of $8.69 (Possible Value Trap). The stock has 1 warning sign investors should review.

Lipella Pharmaceuticals's other current assets for the quarter that ended in Sep. 2025 was $0.22 Mil.

Lipella Pharmaceuticals's quarterly other current assets increased from Mar. 2025 ($0.51 Mil) to Jun. 2025 ($0.61 Mil) but then declined from Jun. 2025 ($0.61 Mil) to Sep. 2025 ($0.22Mil).

Lipella Pharmaceuticals's annual other current assets declined from Dec. 2022 ($0.56 Mil) to Dec. 2023 ($0.10 Mil) increased from Dec. 2023 ($0.10 Mil) to Dec. 2024 ($0.35 Mil).


Lipella Pharmaceuticals Other Current Assets Related Terms


Lipella Pharmaceuticals Other Current Assets Historical Data

* Premium members only.

The historical data trend for Lipella Pharmaceuticals's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lipella Pharmaceuticals Other Current Assets Chart

Lipella Pharmaceuticals Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Other Current Assets
0.02 0.09 0.56 0.10 0.35

Lipella Pharmaceuticals Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Other Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.70 0.35 0.51 0.61 0.22
LIPO
35GF Score
Lipella Pharmaceuticals Inc LIPO
Other Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lipella Pharmaceuticals Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.

Frequently Asked Questions Learn more about Other Current Assets →
What does a Other Current Assets of $0.22 Mil mean?
Lipella Pharmaceuticals (LIPO) has a Other Current Assets of $0.22 Mil as of Sep. 2025. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on Lipella Pharmaceuticals.
Is Lipella Pharmaceuticals' Other Current Assets too high?
Lipella Pharmaceuticals' current Other Current Assets is $0.22 Mil. Overall, Lipella Pharmaceuticals has a GF Score™ of 35/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lipella Pharmaceuticals' Other Current Assets compare to IOBTQ and WINT?
Lipella Pharmaceuticals' Other Current Assets of $0.22 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Assets for a Biotechnology company?
A good Other Current Assets depends on the Biotechnology industry context. However, Other Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Assets mean?
A high Other Current Assets can signal that a stock is expensive relative to its fundamentals. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on Lipella Pharmaceuticals. Lipella Pharmaceuticals's current Other Current Assets is $0.22 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lipella Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Lipella Pharmaceuticals (LIPO) is currently considered Possible Value Trap. The stock's GF Value™ is $8.69, compared to a current price of $0.13 — trading 98.5% below its estimated fair value. The current Other Current Assets is $0.22 Mil. Lipella Pharmaceuticals' overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Assets calculated?
Other Current Assets is calculated from a company's financial statements. For Lipella Pharmaceuticals (LIPO), the current Other Current Assets is $0.22 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lipella Pharmaceuticals (LIPO) Overvalued in 2026?

Based on GuruFocus' analysis, Lipella Pharmaceuticals stock appears to be undervalued. The current stock price of $0.13 is trading 98.5% below its estimated GF Value™ of $8.69. GuruFocus considers Lipella Pharmaceuticals to be Possible Value Trap.

Key valuation signals for LIPO:

  • Other Current Assets: $0.22 Mil
  • GF Value™: $8.69 vs. price of $0.13 (98.5% below fair value)
  • GF Score™: 35/100 with 1 warning sign

No single metric tells the full story. See the LIPO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Lipella Pharmaceuticals Business Description

Address 7800 Susquehanna Street, Suite 505, Pittsburgh, PA, USA, 15208
Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410, which can be helpful in the treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.
35GF Score

Get the complete analysis for LIPO

Other Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.13
Price
$8.69
GF Value